Return to Listing

7 result(s) for Breast Cancer

PI Name Protocol # Title
Kathleen Kemmer IRB00006256 I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Kathleen Kemmer IRB00009076 A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
Charlotte Kubicky IRB00009340 Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Paul Spellman IRB00010163 Reconstructing the Tumor Genome in Peripheral Blood
Matthew Taylor IRB00010605 A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies
Jacqueline Vuky STUDY00015006 A Phase III, Double-Blind Placebo-Controlled, Randomized Study of Taselisib plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer who have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy.
Arpana Naik STUDY00015164 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080